The impact of histological variants of urothelial carcinoma on clinical outcomes following trimodality bladder-sparing chemoradiation
Over 90% of bladder tumours are urothelial (transitional cell) carcinomas; most of the remainder are pure squamous cell carcinoma (3–5%) and adenocarcinoma (<2%). Invasive urothelial carcinoma (UC) shows diversity in its morphology in pure form, but divergent differentiation is also recognise...
Main Authors: | Kiltie, A, Browning, L |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2017
|
Similar Items
-
Radical cystectomy for bladder urothelial carcinoma with aggressive variant histology
by: Vahid Mehrnoush, et al.
Published: (2022-09-01) -
Trimodal Therapy in Esophageal Squamous Cell Carcinoma: Role of Adjuvant Therapy Following Neoadjuvant Chemoradiation and Surgery
by: Xiaokun Li, et al.
Published: (2022-07-01) -
Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial
by: C.F. Stockem, et al.
Published: (2023-08-01) -
Variant Histology: The Impact on Oncological Outcomes of Patients with Urothelial Carcinoma of The Bladder Treated with Radical Cystectomy
by: Berk Hazır, et al.
Published: (2021-12-01) -
State-of-the-art chemoradiation is no substitution for trimodality approach in the treatment of locally advanced thoracic esophageal squamous cell carcinoma
by: Hsin-Yi Yang, et al.
Published: (2023-08-01)